Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 17, 2022
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
[ Thu, Mar 17th 2022
] - WOPRAI
Wed, March 16, 2022
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
[ Wed, Mar 16th 2022
] - WOPRAI
Raghuram Selvaraju Maintained (BBIO) at Strong Buy with Decreased Target to $22 on, Mar 16th, 2022
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $24 to $22 on, Mar 16th, 2022.
Raghuram has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $18 on, Friday, March 11th, 2022
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $26 on, Wednesday, March 9th, 2022
